EverHint – Momentum Swing — Explosive Volume Breakout for Mar 26, 2026 – 2 Signals – Healthcare Leads (1)
What This Signal Is (Quick)
Explosive Volume Breakout is a momentum swing trading strategy focused on Breakouts with 2.5x+ volume surge - institutional buying pressure.
Signal Type: Breakout (momentum continuation)
What Makes This Signal:
- Stock showing strong momentum near or at highs
- Increased volume confirms institutional interest
- Breaking out or consolidating near resistance
- Breakouts with 2.5x+ volume surge - institutional buying pressure
Ideal For: Traders seeking breakouts with exceptional volume confirmation
Key Criteria:
-
Strong RSI momentum (configurable thresholds)
-
Volume surge above average
-
Price momentum confirmation
-
Minimum ADV: $25M+ (varies by variant)
-
Earnings buffer: 7 days pre/post earnings
-
Variant-specific filters applied
Holding Period: 1-4 weeks
Risk Level: Medium-High
How We Ranked Today
Ranked by composite momentum score (higher = stronger momentum)
📊 Momentum Swing — Explosive Volume Breakout Signals (2 Total)
Ranked by score:
| Rank | Ticker | Company | Sector | Last ($) | Score | Vol Thrust | @52w | Insider Net | Days → Earnings | Est EPS | Mkt Cap ($B) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TERN | Terns Pharmaceuticals,... | Healthcare | 53.17 | 0.300 | 2.73x | 0.0% | $-3.0M | — | $-1.63 | 4.8 |
| 2 | CRUS | Cirrus Logic, Inc. | Technology | 148.69 | 0.000 | 3.19x | 0.0% | $-2.9M | 39 | $8.88 | 7.6 |
Field Notes
Sector concentration: Healthcare (1), Technology (1)
Insider selling: CRUS (Cirrus Logic, Inc., $-2.9M), TERN (Terns Pharmaceuticals, Inc., $-3.0M)
Data coverage: 100.0% insider, 0.0% congressional, 50.0% earnings, 100.0% analyst, 100.0% news
Peer Analysis
Understanding how these stocks relate to their industry peers:
CRUS (Cirrus Logic, Inc.): Leads 10 peers: OLED ($93.55, -3.4%), ONTO ($204.75, -7.4%), KD ($12.82, +1.3%), SMTC ($74.16, -7.3%), DLB ($58.73, +0.1%) | Peer of: ALGM ($31.23, -4.3%), CAMT ($159.86, -8.7%), DLB ($58.73, +0.1%) and 8 more
TERN (Terns Pharmaceuticals, Inc.): Leads 9 peers: ORIC ($12.38, +5.8%), PGEN ($3.90, +25.8%), IMTX ($9.77, +0.3%), ELVN ($39.29, +10.6%), AMLX ($13.47, -2.6%) | Peer of: BBNX ($11.52, +1.9%), IMTX ($9.77, +0.3%), KMTS ($19.68, -4.4%) and 7 more
Recent Headlines
CRUS (Cirrus Logic, Inc.)
- Apple Expands Its US Manufacturing Program With Bosch, Cirrus Logic and Others (source)
- Apple adds Bosch, Cirrus Logic, others to US manufacturing program, to invest $400 million (source)
- Cirrus Delivers Strong 2025 Performance (source)
- Cirrus Logic Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 (source)
TERN (Terns Pharmaceuticals, Inc.)
- Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN (source)
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) (source)
- Nasdaq, Dow Jones finish session ahead, oil price softens as US pushes for Iran peace talks (source)
- Dow, Nasdaq Higher Despite U.S.-Iran Peace Deal Uncertainty (source)
- Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst (source)
- Merck to acquire Terns Pharmaceuticals for $6.7B (source)
- Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders (source)
- TERN Stock Alert: Halper Sadeh LLC is Investigating Whether Terns Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders (source)
- Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline (source)
- Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma (source)
- Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns (source)
- Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) (source)
- Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) (source)
- Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports (source)
- As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? (source)
- Terns Pharmaceuticals (NASDAQ:TERN) Reaches New 1-Year High – Should You Buy? (source)
Market Context
Broad market indices declined notably today, with the S&P 500 down 1.76%, Nasdaq dropping 2.34%, and Dow Jones falling 1.01%. The VIX surged 10.86% to 28.08, signaling heightened volatility and investor unease. For momentum swing explosive volume breakout strategies, this environment amplifies intraday swings, potentially fueling sharp breakouts on high volume. However, the elevated VIX also increases the risk of false signals and rapid reversals, demanding tighter risk management to capture explosive moves amid choppy conditions.
The prevailing downtrend across major indices reflects waning risk appetite, which can suppress sustained momentum in growth-oriented plays while favoring defensive rotations. With healthcare as the top sector generating the two signals, this aligns with potential sector rotation toward resilience amid broader weakness. Breakout strategies may thrive here if volume confirms healthcare strength, but overall bearish momentum could cap upside, turning explosive moves into short-lived swings.
Traders should monitor VIX levels closely, as sustained elevation above 28 could extend intraday volatility beneficial for swing captures, yet the risk-off tone tempers conviction in breakouts outside defensive sectors like healthcare.
Sharing Call-to-Action
💪 If this gave you insight, a quick like, share, or subscribe supports the continued work behind EverHint.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/